By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Evercyte adds placenta/amnion derived MSCs to its ‘cell factory’ lines
Vienna, Austria: – Innovative biotech manufacturer Evercyte GmbH has announced a significant new addition to its range of cell line products.
From December 2021, Evercyte has been offering three new mesenchymal stem cells (MSC) line derived from placental tissue (chorionic plate) and amniotic membrane purposed for production of extracellular vesicle (EV) exosomes.
Mesenchymal stem cells from placental tissue and amniotic membrane have attracted increasing attention in life science communities, being reported to exert potent therapeutic effects. Examples include promoting angiogenesis, inducing liver regeneration or influencing the immune system.
Evercyte’s latest P-MSC/TERT308 (placental-derived amnion), RA-MSC/TERT308 (reflected amnion) and CP-MSC/TERT308 (chorionic plate) cell lines all show typical markers and functions of MSCs. These cell lines therefore represent valuable models for studying processes such as differentiation, inflammation, tissue homeostasis and repair.
In recent years evidence has accumulated that the potency of mesenchymal stem cells at least in part is mediated by secreted EVs. The new cell lines have been established under conditions that will allow production of EVs for clinical applications.
Unlimited growth in vitro
Evercyte Chief Operating Officer Dr. Regina Grillari commented: “We are very pleased to present our new telomerized placenta- and amnion-derived cell lines that can be grown without limitations in vitro while maintaining cell type specific markers and functions.”
“Moreover, our new cell lines have been established under xeno-free conditions with full documentation of any manipulation step and extracellular vesicles secreted by the cells under GMP conditions could provide new therapeutic approaches,” Dr. Grillari added.
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including Wharton’s Jelly, adipose tissue, bone marrow, and placenta.
By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in-vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
Click on New mesenchymal stem cell lines from placental tissue for production of exosomes to see original announcement.
Click on P-MSC/TERT308 placental-derived amniotic membrane mesenchymal stem cells for full product information.
Click on RA-MSC/TERT308 reflected amniotic membrane mesenchymal stem cells for full product information.
Click on CP-MSC/TERT308 placenta / chorionic plate mesenchymal stem cells for full product information.